GlassScriptPhysician profile
Ryan Lee Burdick
NPI 1881970572
$1,539.86
in general payments reported to CMS, 2019-2025
25 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $264 · 2023: $297 · 2024: $328 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $296.22 | 2021-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $249.91 | 2021-2025 | Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.71 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $98.12 | 2023-2025 | |
| Novo Nordisk INC | $68.56 | 2021-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $61.11 | 2021-2023 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $59.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.78 | 2021-2025 | Relistor |
| Dexcom, INC. | $45.82 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $44.42 | 2022-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $42.54 | 2022-2025 | |
| Abbott Laboratories | $41.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.59 | 2023 | Xarelto |
| Abbvie INC. | $36.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $27.62 | 2025 | Nuzyra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $26.88 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $26.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.54 | 2021 | |
| Braeburn INC. | $21.43 | 2024 | Brixadi |
| Exact Sciences Corporation | $19.94 | 2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $19.46 | 2023 | Lyvispah |
| Mylan Specialty L.P. | $17.48 | 2022 | |
| Merck Sharp & Dohme LLC | $15.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Burdick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.